T2, scientifically speaking, is 3,5-diiodo-l-thyronine and has had studies published by the NIH supporting claims of increased energy through optimizing oxidation and therefore energy expenditure.
A second study was conducted to explore these findings further in 2011. Antonelli et al at the University of Pisa, Italy, engineered an experiment that investigated long term administration of T2 on humans.
Two subjects, with normal thyroid function, volunteered to receive the T2 compound. Their body weight, body mass index, blood pressure, heart rate, electrocardiogram, thyroid and liver ultrasonography, glycemia, total cholesterol, triglycerides, free T3 (FT3), free T4 (FT4), T2, thyroid stimulating hormone (TSH) and RMR were assessed and recorded at baseline and at the end of treatment.
Results
It was found that, in both participants, RMR increased considerably after treatment and after continuing the T2 usage for a further 3 weeks (at 300 mcg/day), body weight was reduced significantly (p<0.05) (about 4%), while the serum levels of FT3, FT4 and TSH, were unchanged.
It is also important to note that there were no cardiac side effects observed in either participant and that no significant change was observed in the same participants when receiving the placebo.